Protein Informatics and Vaccine Development: Cancer Case Study

Title:Protein Informatics and Vaccine Development: Cancer Case Study

Volume: 22 Issue: 26

Author(s): Saroj Verma, Neeraj Masand, Rameshwar S. Cheke and Vaishali M. Patil*

Affiliation:

• Department of Pharmaceutical Chemistry, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, Uttar Pradesh, India

Abstract: Clinical translation is a challenging step in the development of cancer vaccines and is found to be related to the complex nature of cancer immunology. Vaccine-based therapeutic strategies for cancer have gained consideration with the advent of vaccine technology as well as an understanding of cancer immunology. Immunotherapy has been widely used in the treatment of cancer. Some promising candidates have been identified to engineer cancer vaccines like Glycoprotein, Mucin 1, MHC protein, etc. It has benefited from the availability of advanced techniques for rapid identification and selection of proteins for precision engineering. Simultaneously, nanovaccines have been focused on target delivery and artificial intelligence-based approaches for personalized vaccine development. The manuscript summarizes the advances in the development of structurebased cancer vaccines along with the status of clinical studies and applications.

Cite this article as:

Verma Saroj, Masand Neeraj, Cheke S. Rameshwar and Patil M. Vaishali*, Protein Informatics and Vaccine Development: Cancer Case Study, Current Topics in Medicinal Chemistry 2022; 22 (26) . https://dx.doi.org/10.2174/1568026623666221107160636